NLR and CRP at Baseline Versus at the Time of irAE, MACE, or C6-C8 During ICI Treatment
(A) NLR in ICI-treated patients with and without MACE. In patients who did not experience any irAEs, NLR at baseline and C6 to C8 were <10. NLR at baseline was >10 in patients with MACE and patients who had disease progression. NLR increased significantly at the time of MACE and noncardiac irAEs (red bars). (B) CRP in ICI-treated patients with and without MACEs. In patients who did not experience any irAEs, CRP was <20 mg/l at baseline and C6 to C8. CRP was elevated in patients with MACE and in patients with disease progression and who had noncardiac irAEs. At the time of irAE or MACE, CRP was significantly elevated in comparison to baseline CRP. ∗p < 0.05 in comparison to respective baseline values; †p < 0.05 in comparison to baseline values in patients with no irAEs. C6-C8 = cycle 6 to cycle 8; CRP = C-reactive protein; ICI = immune checkpoint inhibitor; irAE = immune-related adverse events; MACE = major adverse cardiac events; NLR = neutrophil-lymphocyte ratio.